Based in Paris, France, within the Cochin University Hospital, Theraclion is supported by an international scientific and medical committee composed of surgeons, interventional radiologists, endocrinologists and nephrologists.

Our goal is to bring innovative breakthrough technologies to the world of healthcare. Theraclion’s solution offers a unique, simple, non-invasive, cost-efficient, outpatient-based alternative for treating primary and secondary hyperparathyroidism.

Theraclion's main shareholder is Truffle Capital, a leading Venture Capital firm in Europe.
The company is also supported by the French Government through its Innovation and Development Fund, OSEO.